Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 253 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... May 2, 2019 Tesco is making it even easier to support life-saving research February 3, 2023 Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... September 30, 2025 Load more HOT NEWS No Link Between Caffeine Consumption and Breast Cancer, Study Finds FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... What Cancer Caregivers Should Know About Hospice Care at Home: A...
